Recently, the Food and Drug Administration (FDA) issued an advisory that sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are associated with a risk of severe urinary tract infection (UTI) (1). They reported 19 patients with life‐threatening sepsis due to UTI and severe pyelonephritis after initiating SGLT‐2 inhibitors who required hospitalization. Some of them required admission to an intensive care unit or dialysis in order to treat acute renal failure.

中文翻译：

---

启动钠-葡萄糖协同转运蛋白 2 抑制剂不会增加严重尿路感染的发生率。


最近，美国食品和药物管理局 (FDA) 发布公告称钠-葡萄糖协同转运蛋白 2 (SGLT-2) 抑制剂与严重尿路感染 (UTI) 的风险相关 (1)。他们报告了 19 名患者在开始使用 SGLT-2 抑制剂后因尿路感染和严重肾盂肾炎而出现危及生命的脓毒症，需要住院治疗。其中一些人需要住进重症监护室或进行透析以治疗急性肾衰竭。